QNRX — Quoin Pharmaceuticals Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1671502 ·
Last close
$3.36
Market Cap
$16.14M
52W High
$23.50
52W Low
$3.25
ADV30
22,301
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -4,923,012 | -4,870,759 | 34,747,044 | 10,099,800 | 6,049,261 |
| Jun 2026 | 0 | — | -5,473,574 | -5,371,042 | 11,969,562 | 3,845,606 | 8,036,891 |
| Mar 2026 | 0 | — | -5,131,210 | -4,997,735 | 15,692,891 | 3,124,523 | 6,919,759 |
| Dec 2025 | 0 | — | -4,520,435 | -4,348,373 | 20,390,569 | 3,818,096 | 7,270,663 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,273,747
Investing CF
$-593,769
Financing CF
$18,045,212
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-12.12
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-81,339,224
Inventory
—
Receivables
—
ST Investments
$6,954,476
EBIT TTM
$-19,145,144
Pretax Income TTM
$-18,665,315
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,290,716 | -15,804,655 | 20,390,569 | 7,270,663 | 13,119,906 | -13,540,994 |
| Dec 2024 | 0 | -9,528,465 | -8,962,472 | 15,709,338 | 6,504,665 | 9,204,673 | -7,857,309 |
| Dec 2023 | 0 | -9,378,504 | -8,686,573 | 12,169,229 | 6,505,213 | 5,664,016 | -7,864,429 |
| Dec 2022 | 0 | -9,257,704 | -9,381,496 | 14,458,063 | 7,051,289 | 7,406,774 | -8,480,732 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
$-18,665,315
OpCashFlow TTM
—
Assets (Latest)
$11,969,562
Forward EPS
$-2.71
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VICP | Vicapsys Life Sciences, Inc. | $16.19M | $0.50 | — |
| CNTX | Context Therapeutics Inc. | $15.71M | $0.17 | — |
| NCEL | NewcelX Ltd. | $15.48M | $2.68 | — |
| MDNAF | Medicenna Therapeutics Corp. | $14.77M | $0.16 | — |
| BOLT | Bolt Biotherapeutics, Inc. | $14.73M | $5.65 | — |
News headlines (Yahoo Finance, 1h cache)
Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
2026-11-06 13:30 · Yahoo
Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results
2026-11-05 13:30 · Yahoo
Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026
2026-10-29 12:30 · Yahoo
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
2026-10-20 10:30 · Yahoo
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
2026-10-14 10:30 · Yahoo
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
2026-10-06 10:30 · Yahoo
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
2026-09-22 12:30 · Yahoo
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
2026-09-10 12:30 · Yahoo
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
2026-09-08 18:12 · Yahoo
Quoin in line for priority review voucher if rare paediatric drug approved
2026-09-08 17:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.